US Patent Issued to Janssen Pharmaceutica on April 29 for "5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors" (Pennsylvania Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,286,429, issued on April 29, was assigned to Janssen Pharmaceutica NV (Beerse, Belgium).

"5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors" was invented by Guozhang Xu (Chesterbrook, Pa.) and Mark J. Macielag (Gwynedd Valley, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereofThe present invention is also directed to pharmaceutical compositions containing such compounds and the use of such compounds in the treatment and/or prophyl...